Updates are available Correction dated 2025-02-18
Click to view Correction: https://doi.org/10.1007/s10815-025-03428-2
-
Authors
Gleicher, Norbert
Barad, David H. https://orcid.org/0000-0002-7980-2369
Patrizio, Pasquale
Gayete-Lafuente, Sonia
Weghofer, Andrea
Rafael, Zion Ben
Takahashi, Shizuko
Glujovsky, Demián
Mol, Ben W.
Orvieto, Raoul
-
Funding
Funding for this research was provided by:
Center for Human Reproduction
- License Information
-
More Information
Article History
Received: 2 August 2024
Accepted: 3 November 2024
First Online: 18 December 2024
Change Date: 17 February 2025
Change Type: Update
Change Details: The original online version of this article was revised to update the name of the fourth author in the author byline from 'Sonya Gayete-Lafuente' into 'Sonia Gayete-Lafuente'.
Change Date: 18 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10815-025-03428-2
Declarations
:
: N.G. and D.H.B. are listed as co-owners of several already awarded and still pending U.S. patents, some claiming benefits from androgen supplementation in women with low functional ovarian reserve, a topic addressed in this manuscript. Others relate to diagnostic and potential therapeutic benefits of AMH, also marginally addressed in this manuscript. N.G. is a shareholder in Fertility Nutraceuticals, LLC, which produces a DHEA product, and is the owner of The CHR., where much of the research reported in this manuscript was performed. N.G. and D.H.B. also receive patent royalties from Fertility Nutraceuticals, LLC. N.G. and D.H.B. in the past have received research support, travel funding, and lecture fees from various Pharma and medical device companies, none, however, over the last three years and none in any way related to this manuscript.
